Abstract
This systematic review and meta-analysis aimed to evaluate the efficacy of intravenous (IV) and nebulized magnesium sulfate for acute asthma in children. Ten randomized and quasi-randomized trials (6 IV, 4 nebulized) were identified through search of databases (PubMed, Cochrane Library, and EMBASE). Intavenous magnesium sulfate treatment was associated with significant effects on respiratory function (standardized mean difference 1.94; 95% CI 0.80,3.08; P=0.0008) and hospital admission (RR 0.55; 95% CI 0.31,0.95; P=0.03). But nebulized magnesium sulfate treatment showed no significant effect on respiratory function (standardized mean difference 0.19; 95% CI–0.01, 0.40; P=0.07) or hospital admission (RR 1.11; 95% CI 0.86,1.44; P=0.42). Authors concluded that IV magnesium sulfate is an effective treatment in children, with significant improvement in pulmonary function and decrease in hospitalization and need for further treatment, but nebulized magnesium sulfate treatment showed no significant effect on respiratory function or hospital admission and further treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
